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Introduction
There has been growing interest in cancer diagnostics using 
circulating tumor-derived nucleic acids as a source for tumor 
biomarkers. This approach is particularly attractive because 
it allows detection of genetic mutations in the tumor as well 
as quantification of mutant sequences present in the sam-
ple. Biofluid-based analysis is less invasive than performing 
tumor biopsy, extends the range of a single biopsy by offering 
the potential to mirror the genetic diversity within a tumor, and 
also enables longitudinal measurements to monitor genetic 
changes in tumor over time.1,2
A new promising source of biofluid-based biomarkers is 
extracellular vesicles (EVs); they are actively released from 
normal as well as cancer cells both in vitro and in vivo,3 with 
upregulated release from many tumor cells, as compared 
with normal cells.3–6 They include several types of membrane-
bound vesicles, such as exosomes, shed EVs, oncosomes 
and apoptotic blebs.7 EVs contain a diverse repertoire of 
genetic material and protect their cargo from the destructive 
action of enzymes, such as RNases,4 thus enabling a stable 
enrichment of nucleic acids from biofluids. RNA from glioblas-
toma (GBM) serum EVs has previously been used to detect 
the EGFRvIII mutation.4 Tumor-derived EVs are also found in 
the cerebrospinal fluid (CSF),8 and may provide valuable bio-
marker information about the tumor origins and status. Several 
diagnostic techniques utilize CSF for analysis; however, most 
of them do not provide any molecular or genetic information on 
malignancies. In vivo techniques, including CSF cytology, clini-
cal findings and neuro-imaging, as well as in vitro techniques 
like immunocytochemistry, flow cytometry and PCR have so 
far only been informative for leptomeningeal cancers, in which 
tumor cells have entered and disseminated within CSF.9
Highly sensitive technologies must be used when detect-
ing mutations in the background of wild-type sequence and 
the optimal assay may vary according to the type of genetic 
alteration to be detected. For example, large gene/transcript 
deletions like EGFRvIII are relatively easy to detect in the 
background of wild-type sequences using well optimized 
allele-specific PCR assays.4 In contrast, single nucleotide 
mutations are very difficult to pick up when the fraction of 
mutated transcripts is low in a background of wild-type 
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Development of biofluid-based molecular diagnostic tests for cancer is an important step towards tumor characterization and 
real-time monitoring in a minimally invasive fashion. Extracellular vesicles (EVs) are released from tumor cells into body fluids 
and can provide a powerful platform for tumor biomarkers because they carry tumor proteins and nucleic acids. Detecting rare 
point mutations in the background of wild-type sequences in biofluids such as blood and cerebrospinal fluid (CSF) remains 
a major challenge. Techniques such as BEAMing (beads, emulsion, amplification, magnetics) PCR and droplet digital PCR 
(ddPCR) are substantially more sensitive than many other assays for mutant sequence detection. Here, we describe a novel 
approach that combines biofluid EV RNA and BEAMing RT-PCR (EV-BEAMing), as well droplet digital PCR to interrogate 
mutations from glioma tumors. EVs from CSF of patients with glioma were shown to contain mutant IDH1 transcripts, and 
we were able to reliably detect and quantify mutant and wild-type IDH1 RNA transcripts in CSF of patients with gliomas. 
EV-BEAMing and EV-ddPCR represent a valuable new strategy for cancer diagnostics, which can be applied to a variety of 
biofluids and neoplasms.
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sequences, and even well optimized allele-specific PCRs can 
rarely detect mutations at a frequency of less than 1%.10 To 
increase the sensitivity of EV RNAs as tumor biomarkers, we 
adapted a well established and highly sensitive form of digital 
PCR known as BEAMing (Beads, Emulsions, Amplification, 
Magnetics)11 to interrogate the mRNA within EVs for the pres-
ence of tumor specific mutations. BEAMing PCR is a highly 
sensitive and quantitative technique that has been success-
fully applied to the mutational analysis of circulating DNA even 
when the mutation is as rare as 0.01%.12–14 We also used a 
droplet digital PCR (ddPCR) technology, which creates mil-
lions of uniform 5 picoliter-volume droplets per sample for 
counting applications including rare allele detection and vali-
dation in tumor and cell-free plasma,15–17 and assessment of 
DNA quality before sequencing.18 Neither of these technolo-
gies have previously been used to quantify rare mutations at 
the RNA level or been tested on EV nucleic acids.
The IDH1 mutation was chosen for analysis because of its 
high relevance in tumor pathogenesis. Analysis was carried 
out for wild-type (G395) and mutant (A395) sequences in the 
mRNA transcripts for isocitrate dehydrogenase 1 (IDH1), with 
the latter resulting in a substitution of arginine for histidine at 
amino acid position 132 (R132H;).19 Functional studies have 
revealed that the H132 mutant protein catalyzes the conver-
sion of α-ketoglutarate into 2-hydroxyglutarate (2-HG), a sus-
pected oncometabolite.19,20 Mutant IDH1 was first reported in 
colorectal cancer21 and has been identified in acute myeloge-
nous leukemia and in GBM through genome wide mutational 
analysis.22,23 A subsequent study found mutations in IDH1/2 
in almost 80% of grades II and III astrocytomas, oligoden-
drogliomas and secondary GBMs,24 with the most common 
mutant being the G395A substitution. Microarray RNA pro-
file analysis indicates that IDH1 mutations in gliomas occur 
primarily in the proneural subtype, making them distinctive 
from the classical, neural, and mesenchymal subtypes which 
rarely show this mutation25 and suggesting that this mutation 
is correlated to an improved prognosis and a potential strati-
fier for treatment options. Indeed, mutations in the IDH1 gene 
in all low glioma grades, as well as secondary GBMs, predict 
longer survival and better response to temozolomide treat-
ment.26,27 Although several studies have reported that levels 
of 2-HG increase up to ~100-fold in glioma cell lines express-
ing mutant IDH1,28 a recent study failed to show a correlation 
between serum levels of 2-HG with IDH1/2 mutation status 
or tumor size in patients with glioma,29 suggesting that quan-
tifying mutant mRNA copy number rather than the metabolite 
may provide more accurate information about tumor status.
Using BEAMing and ddPCR on mRNA from EVs, we reli-
ably identified the mutant IDH1 mRNA in CSF-derived EVs 
collected at the time of brain tumor surgery from patients bear-
ing mutant IDH1 glioma tumors, but not in serum-derived EVs. 
Under the conditions used, both assays gave similar levels of 
sensitivity and specificity in CSF samples. We also showed that 
CSF-derived EVs from patients with tumor have higher levels of 
IDH1 mRNA than CSF EVs from controls. A higher copy num-
ber of IDH1 mRNA was also found in serum from patients with 
tumor as compared with that from controls. In conclusion, we 
report that CSF-derived EVs provide a platform for detection of 
brain tumor specific biomarkers and that digital PCR platforms 
work well for detection of rare mutations in EV mRNAs.
Results
Isolation of serum and CSF-derived EVs for RNA-based 
mutation analysis
To prepare for EV-BEAMing (Figure 1) and ddPCR of EV 
RNA (Figure 2) analysis, we first isolated EVs from frozen 
biobanked serum and CSF of patients with grades II, III, and 
IV gliomas, as well as controls. Cryo-transmission electron 
microscopic and electron microscopic (EM) analysis of pel-
leted CSF-derived EVs and plasma, revealed round double-
lipid membrane vesicles, sometimes with vesicles within 
vesicles and a size range of approximately 30–300 nm in diam-
eter (Figure 3a). Nanosight tracking analysis revealed that 
GBM serum and CSF samples contained particles typically 
30–300 nm in diameter, with an average of 4.2 × 1012 particles/
ml ± 8.9 × 1011 SD (n = 3) in serum and 8.7 × 109 ± 1.7 × 109 
SD particles/ml (n = 3) in CSF, making the particle number 
in CSF about 300-fold lower than in serum  (Figure 3b). The 
quality of the extracted RNA from serum and CSF samples 
was assessed using the Agilent Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA) and was confirmed to be similar to 
previously shown profiles3 (see Supplementary Figure S1). 
EV-derived RNA was then reverse transcribed into cDNA and 
10% was used as input for RT-PCR. The remaining cDNA was 
preamplified (14 cycles) using dual-biotin–labeled forward 
primer and a reverse primer, used as input for EV-BEAM-
ing as well as ddPCR and analyzed for IDH1 mRNA copy 
number and the G395 or A395 sequences in IDH1. FACS, 
ddPCR, and qPCR results were used to quantify the number 
of wild-type and mutant IDH1 mRNA copies present in EVs. 
In parallel, the tumor tissue was also typed for the A395 IDH1 
mutation by genomic DNA sequencing.
IDH1 mRNA copies in serum and CSF-derived EVs
EV mRNA was reverse transcribed into cDNA and used to per-
form copy number analysis for IDH1 transcripts using quan-
titative PCR. Serum from patients with glioma contained an 
average of 7,800 ± 6,600 SD (n = 10) copies of IDH1 mRNA/
ml (Figure 4b), whereas serum from controls had 245 ± 65 
SD (n = 4) copies of IDH1 mRNA/ml (Table 1; P ≤ 0.007). 
The copies of IDH1 mRNA in CSF from patients with glioma 
tended to be higher than in serum from patients with glioma, 
mean 106,000 ± 150,000 SD (n = 14) copies mRNA/ml in CSF 
(Figure 4b) and 7,800 ± 6,600 SD IDH1 mRNA/ml serum (P 
≤ 0.03 n = 10). IDH1 mRNA copies were much lower in CSF 
from non-tumor controls (40 copies mRNA/ml; n = 2) as com-
pared with CSF from patients with glioma (P ≤ 0.02). Note 
that all CSF glioma samples were collected from the CSF 
cisterns before tumor manipulation during surgery, except for 
glioma sample 308 and controls which were collected by lum-
bar puncture; this may partially explain the difference in IDH1 
mRNA copy number. Interestingly, the lumbar puncture CSF 
sample 308 had the highest percentage of mutant IDH1 in 
the EVs.
CSF EVs from patients with tumor carry the mutated 
IDH1 A395
For EV-BEAMing analysis, 50% of the IDH1 cDNA product 
was PCR amplified (14 cycles) and used as input for BEAM-
ing as well as ddPCR, as described in the Materials and 
Methods. For BEAMing PCR, we interrogated the identity 
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of the amplicons attached to each bead using an Alexa 
Fluor 488–labeled probe specific for the wild-type IDH1 
sequence, an Alexa Fluor 647–labeled probe specific for 
the A395 mutant sequence, and a Pacific Blue (PB)–labeled 
control probe specific for a sequence common to both the 
mutant and wild-type sequences. This results in individual 
beads that are colabeled for PB (blue fluorescence) and 
either Alexa Fluor 488 (green fluorescence) or Alexa Fluor 
657 (red fluorescence). FACS analyses were performed by 
initially gating on 100,000 (single bead) events which were 
PB-positive. Percentage mutant signal was calculated using 
the PB-positive population, thus, excluding beads that had 
no fluorescence and those with both wild-type and mutant 
fluorescence  (Figure 4a; see Materials and Methods). Drop-
let digital PCR was also performed using the same probe 
sequences but for this assay they were labeled with FAM 
and VIC fluorescence (mutant and wild-type, respectively). 
After ddPCR amplification, the samples were transferred to 
a microfluidic chip for fluorescence measurements. Custom 
software was used to define gates and count the number 
of single molecule amplified droplets within each gate. For 
BEAMing PCR, the preamplified PCR products were diluted 
~1:15,000 (10 pmol/reaction), whereas they were diluted 
1:106 for ddPCR.
Figure 1 Overview of EV-BEAMing. EVs from serum or CSF samples were pelleted at 100,000g for 80 minutes and processed as follows: 
(1) RNA was extracted and (2) analyzed for total yield and quality using the Bioanalyzer (Agilent). (3) RNA was then reverse transcribed 
into cDNA and 1/2 of the sample was used to determine the IDH1 cDNA copy number inside EVs by (4) qPCR analysis. (5) The remaining 
sample was preamplified (14 cycles) and used as input for BEAMing PCR. The resulting DNA-coated beads were interrogated with sequence-
specific fluorescent probes to produce beads with wild-type (green) and mutant (red) profiles. (6) The percentage of beads with mutant DNA 
was determined by FACS and used in conjunction with the qPCR data to determine the minimum number of copies present to allow reliable 
detection of the mutant message.
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We analyzed the CSF of patients with grade II (n = 2), grade 
III (n = 4), and grade IV (n = 2) gliomas harboring the A395 
mutation in IDH1, as well as that of grade II glioma (n = 1) and 
grade IV GBMs (n = 5) that possessed only wild-type IDH1 
alleles and detected the mutant message in five out of eight of 
the mutant tumor samples and none of the wild-type samples 
(Figure 4c; Table 1). Quantitative PCR analysis revealed that 
the five mutant positive CSF samples had a wide range of 
copies of IDH1 message/cDNA from 1 ml of CSF (ID# 308, 
2,262 copies; ID# 2244, 3,000 copies; ID# 2160, 5,210 copies; 
ID# 2199, 10,240 copies; and ID# 2510, 281,320 total copies 
of IDH1 message/cDNA, in the five samples respectively). The 
percentage of mutant message detected in the five samples 
was 8.0%, 5.0%, 1.5%, 0.4%, and 8.5%, respectively, sug-
gesting that about 181, 150, 78, 41, and 23,912 amplifiable 
copies of the mutant message were obtained from EVs in 1 ml 
CSF from these patients. Neither of the two non-tumor control 
CSF samples, collected during routine neurological exami-
nation displayed any mutant events (Table 1). Droplet digital 
PCR also detected the same mutant samples but the percent-
age of the mutant message was generally twice as high; ID#s 
308 = 23.7%, 2244 = 10.6%, 2160 = 3.9%, 2199 = 1.0%, and 
2510 = 20.4%. The reasons for these platform differences are 
still being investigated. We also analyzed serum samples from 
seven patients with IDH1 mutant tumors (grades II, III, and 
IV), as well as four healthy control serum samples and the 
mutation was not detected in any of the seven IDH1 mutant 
serum samples or control samples (Table 1). Both digital PCR 
methods performed equally, although the dilutions of the pre-
amplified PCR product differed greatly.
Discussion
Here, we show that the mutational profile of IDH1 mutated 
brain tumors can be measured in CSF without the need for 
a biopsy of the tumor. We can measure the presence as well 
as the abundance of the mutated transcript found in CSF 
EVs with digital PCR methods such as BEAMing or ddPCR. 
This method may be useful as a non-invasive tool to verify 
and subtype brain tumors in cases where the tumor location 
makes biopsies risky or impossible. It may also be used to 
subtype tumors for drug clinical trial enrollment. BEAMing 
and ddPCR assays had the same sensitivity and specific-
ity levels using CSF. Serum contains vesicles from many 
normal processes naturally occurring in the blood such 
as maturation of reticulocytes and platelet activation. The 
Figure 2 Overview of droplet digital PCR. The RainDrop ddPCR workflow consisted of three steps: (1) PCR reaction mixtures for each 
sample were pipetted into one of eight wells on the Source microfluidic chip, which was next placed above empty PCR tubes in the RainDrop 
Source. Pressure-driven air flow forced the aqueous mixture into the chip along with a surfactant-containing fluorocarbon oil to generate 
five picoliter droplets, and then deposited automatically into the PCR tube strip. (2) The PCR tube strip was placed into a standard thermal 
cycler for endpoint PCR amplification, with single-target-molecule-containing droplets resulting in specific probe hydrolysis (PCR+) and bright 
fluorescence and the majority of droplets, containing no target molecule, resulting in only background probe fluorescence (PCR−). (3) Each 
droplet’s fluorescence was detected using a Sense microfluidic chip. The fluorescence was detected and processed into a two-dimensional 
scatter plot display, custom software was used to draw appropriate gates for each droplet endpoint cluster, and the number of droplets within 
each gate was counted.
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CSF may therefore be a more enriched source of the brain 
tumor–derived vesicles and therefore easier to detect than 
in serum. Interestingly, the number of copies of IDH1 mutant 
mRNA in CSF EVs from patients with tumor was significantly 
higher than in controls (Table 1). Noteworthy is the differ-
ence in sampling site, most CSF samples from patients 
with tumor were collected upon opening of the dura mater, 
near the primary tumor, whereas CSF control samples were 
Figure 4 Correlation of samples characteristics with the detection of the mutant IDH1. (a) BEAMing FACS plot of one representative 
mutant positive samples indicating the mutant (Q1) and wild-type populations (Q4). (b) qPCR analysis of the IDH1 mRNA copy number in 
CSF (n = 14) and serum (n = 10) samples from all GBM patients analyzed that are wild-type or mutant for the IDH1 gene (±SEM). (c) Tumor 
volumes (left panel) and IDH1 mRNA copy numbers (right panel) in 1 ml of CSF from the mutant IDH1 glioma samples analyzed (n = 8), 
corresponding to detected or non detected, in mRNA as determined by EV-BEAMing assay and ddPCR.
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collected by lumbar puncture. Patient sample 308 was col-
lected by lumbar puncture and shows that mutation detec-
tion can be done from lumbar puncture, and this sample 
actually had the highest percentage of mutant IDH1 tran-
scripts. The high levels of IDH1 mRNA in cisternal CSF from 
patients with glioma collected during surgery compared with 
control patients collected by lumbar puncture may be due to 
a higher number of EVs released by tumor or normal cells 
in the vicinity of the tumor or from debris from normal cells 
in the mechanical process of opening the dura mater. Two of 
the false negative samples (in the EVs) had unusually high 
copy numbers of WT IDH1 (~400,000 WT copies; Table 1) 
that could have masked the detection of the mutant. For this 
purpose, lumbar puncture samples may be preferred for this 
analysis.
Using the BEAMing assay we determined that between 
41 and 181 mutant IDH1 mRNA transcripts were present in 
1 ml CSF in four samples, with one sample having as many 
as 23,912 mutant copies. ddPCR detected roughly twice as 
many mutated RNA transcripts per ml CSF (ID#s 308 = 536, 
2244 = 318, 2160 = 203, 2199 = 102, and 2510 = 57,389). 
Interestingly, two of the three IDH1 mutant positive tumors 
that were not detected by either method were grade II CSF 
samples (IDs# 2287 and 2516, Table 1). The third sample 
that was not detected was a grade III tumor (ID# 2513) 
that had the smallest tumor size in grade III category sug-
gesting a possible correlation with grade as well as tumor 
size  (Figure 4c). Further studies with a larger number of 
samples will address this correlation more thoroughly. The 
IDH1 mutant detection sensitivity in serum will need further 
Table 1 CSF and serum samples characteristics
Sample ID Biofluid Diagnosis Location
Tumor IDH1 
status
Tumor volume 
(cm3)
BEAMing/
ddPCR
Total IDH1 
copy number
BEAMing % 
mutant
ddPCR %  
mutant
2251 CSF GBM Grade IV RFL WT 66 Neg 30,000 0 0
2231 CSF GBM Grade IV LT WT 40 Neg 10,240 0 0
2163 CSF GBM Grade IV RT WT 55 Neg 80,000 0 0
2509 CSF GBM Grade IV RFL WT 4 Neg 10,920 0 0
2511 CSF GBM Grade IV RTPO WT 64 Neg 186,440 0 0
2515 CSF PX Grade II LTL WT 0.64 Neg 28,700 0 0
2199 CSF OA Grade III LFB G395A 26 Pos 10,240 0.4 1
2160 CSF AOD Grade III RFL G395A 147.6 Pos 5,210 1.5 3.9
2244 CSF AOD Grade III RFL G395A 35.2 Pos 3,000 5 10.6
2510 CSF GBM/OD Grade IV RFL G395A 15.84 Pos 281,320 8.5 20.4
308 CSF GBM LI G395A 73.6 Pos 2,262 8 23.7
2287 CSF OA Grade II RT G395A 7.9 Neg 30,000 0 0
2513 CSF AOD Grade III LFB G395A 17.55 Neg 404,120 0 0
2516 CSF OD Grade II RFT G395A 23.47 Neg 404,120 0 0
1104 Serum AA Grade III/IV LFT G395A 37.5 Neg 1,000 0 0
698 Serum GBM Grade IV RPFL G395A 9.93 Neg 5,000 0 0
3775a Serum OA grade II RF G395A 20 Neg 1,000 0 0
1093 Serum RhgGBM LT G395A 13.2 Neg 2,500 0 0
2510 Serum GBM/OD Grade IV RFL G395A 15.84 Neg 6,660 0 0
2513 Serum AOD Grade III LFB G395A 17.55 Neg 10,200 0 0
2516 Serum OD Grade II RFB G395A 23.47 Neg 5,920 0 0
2509 Serum GBM Grade IV RFL WT 4.1 Neg 6,980 0 0
2511 Serum GBM Grade IV RTPO WT 64.38 Neg 22,920 0 0
2515 Serum PXA Grade II LTL WT 0.635 Neg 16,280 0 0
Control CSF Healthy NA WT NA Neg 40 0 0
Control CSF Healthy NA WT NA Neg 40 0 0
Control Serum Healthy NA WT NA Neg 250 0 0
Control Serum Healthy NA WT NA Neg 160 0 0
Control Serum Healthy NA WT NA Neg 320 0 0
Control Serum Healthy NA WT NA Neg 250 0 0
AA, anaplastic astrocytoma; AOD, anaplastic oligodendroglioma; CSF, cerebrospinal fluid; LFB, left frontal, near Broca’s area; LI, left insula; LT, left temporal; LTL, 
left temporal lobe; NA, not applicable; OA, oligoastrocytoma; OD, oligodendriomas; PX, pleomorphic xanthoastrocytoma; RhgGBM, recurrent high grade GBM; 
RFL, right frontal lobe; RT, right temporal; RTPO, right temporo-parieto occipital; RPFL, right posterior frontal lobe; WT, wild-type.
aSample ID# 2000092.
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optimization, and the relatively low IDH1 mRNA copy num-
ber suggest that increasing the volume of serum input may 
increase the sensitivity of the assay. All tumor-free controls 
included in the study were wild-type for IDH1 mRNA as ana-
lyzed by FACS (Table 1). Future studies will aim to increase 
the copy number input to improve the sensitivity of the assay 
in blood-based assays and to correlate the detection of 
mutant IDH1 with clinical, demographic, MRI and molecular 
neuropathologic studies. Other studies have reported detec-
tion of other tumor biomarkers in blood on DNA, such as the 
EGFR gene amplification in lung adenocarcinomas30 and 
PIK3CA mutations in metastatic breast cancer.31 We have 
previously shown that also DNA can be present in glioma 
EVs;3 however, this study focused only on the RNA fraction.
IDH1 is usually a heterozygous mutation,28 so when 5% 
of the IDH1 transcripts are mutated, approximately 10% of 
the IDH1 transcripts come from the tumor. It may be possible 
to enrich the tumor EV fraction by immunoaffinity methods 
using antigens specific to the tumor cell surface32 or using 
magnetic resonance detection of mutant proteins to poten-
tially increase the sensitivity of mutation assays.33
Information on the mutational profiles of different types of 
gliomas has increased to the point where genomic altera-
tions and expression profiles characteristic of the classical, 
proneural, neural, and mesenchymal glioma subtypes have 
been identified.12 EV-BEAMing or ddPCR on biofluid EVs 
should have high value in monitoring specific subtypes of 
gliomas in a minimally invasive manner. Although obtaining 
CSF is not a routine procedure in patients with brain tumors, 
it is markedly less invasive than obtaining an intracerebral 
biopsy of the tumor. Further extension of this work in clinical 
studies will require focusing on samples derived by lumbar 
puncture, as this is the only feasible sampling methodology 
to perform on a routine basis but this study lays the founda-
tion for lumbar puncture–based CSF mutation analysis stud-
ies in patients. This technology should enable monitoring of 
a variety of mutations and transcript levels in tumors using 
CSF and potentially serum-derived EVs not only when the 
tumor is located in areas with inherent risk of sampling such 
as brain, but also for tumors in other parts of the body. This 
study provides a proof of principle for detection of single base 
pair mutations in tumor RNA using EVs in CSF samples, 
combined with a sensitive digital PCR assays.
Materials and methods
Study design and sample collection. This study was approved 
by the Institutional Review Boards of Massachusetts General 
Hospital, Beth Israel Deaconess Medical Center, and the Uni-
versity of California, Los Angeles. Serum and CSF samples 
from patients and healthy volunteers were collected accord-
ing to approved IRB protocols. Brain tumors were obtained 
at the Massachusetts General Hospital, Beth Israel Deacon-
ess Medical Center and University of California, Los Angeles 
and confirmed by histopathology. The mutational status of 
the IDH1 gene in tumor tissue was determined by genomic 
sequencing or SNaPShot analysis by the Molecular Neuro-
pathology Laboratory at UCLA and Massachusetts General 
Hospital, respectively.
Sample processing. Blood was collected from patients 
undergoing surgical removal of gliomas using BD Vacutainer 
SST tube (BD Biosciences, San Jose, CA), before opening 
of the dura mater, maintained for 30 minutes at room tem-
perature and then centrifuged at 1,300g for 10 minutes. The 
serum was separated from the coagulated blood cells, fil-
tered through a 0.8 μm filter and stored at −80 °C. CSF, also 
collected at surgery from patients with glioma upon opening 
of the dura mater, was centrifuged at 300g for 10 minutes to 
remove cells, and stored at −80 °C. Control CSF samples 
were collected by lumbar puncture from patients with sus-
pected non-malignant, neurological disease whose CSF pro-
file was later found to be normal, and stored at −80 °C. At 
the time of analysis, samples were thawed, centrifuged at 
100,000g for 80 minutes at 4 °C to collect EVs and RNA was 
extracted, as previously described.3 To minimize any risk of 
contamination, tumor tissue was extracted and sequenced 
in one laboratory, whereas serum and CSF EV RNA was 
extracted at a different location in a DNA-free, RNA extrac-
tion facility, and BEAMing and ddPCR were performed at a 
third location.
Extravesicular RNA isolation. Frozen serum or CSF samples 
were thawed (1 ml/sample), diluted to 2.5 ml with sterile PBS 
and centrifuged at 100,000g for 80 minutes. External DNA 
on the EVs was removed using 2 μl of DNAse from the Turbo 
DNA-free kit (Ambion, Foster City, CA), according to manu-
facturer’s recommendations. RNA was purified using the 
miRNeasy Qiagen kit (Qiagen, Valencia, CA) and eluted in 
30 μl RNase-free water. RNA quality was assessed using a 
2100 Bioanalyzer (Agilent) with an RNA 6000 Pico Chip kit 
(Agilent).
Determination of tumor volume. For high grade gliomas with 
significant contrast enhancement, T1-weighted sequences 
after injection of contrast agent were used to define the “tumor 
volume” as the area of contrast enhancement including central 
necrotic tissue. For low grade tumors and tumors without sig-
nificant enhancement, volume was determined using T2 areas 
of hyperintensity. To determine the volume, we measured the 
tumor area in each slice using a region-of-interest method 
(BrainLAB Software; BrainLAB, Feldkirchen, Germany). The 
volumes were calculated by multiplying these resulting areas 
by the slice thickness. The total tumor volume is the sum of the 
volumes calculated for each of the multiple parallel slices.34
Nanosight tracking analysis. Nanosight tracking analysis was 
used to count and size EVs. Serum was processed as above 
and stored at −80 °C. At the time of the analysis the serum 
was diluted 1:5,000 and analyzed using the Nanosight. CSF 
was also stored at −80 °C and diluted 1:50 for Nanosight 
analysis. Both biofluids were diluted in PBS for nanosight 
tracking analysis.
Electron microscopy. CSF samples (500 μl) were thawed and 
ultracentrifuged at 100,000g for 80 minutes. The EV pellet 
was then resuspended in 50 μl of PBS and analyzed by EM. 
2.5 μl of the samples was adsorbed for 30 minutes on carbon 
coated grids that had been made hydrophilic by a 30-second 
exposure to a glow discharge. Excess liquid was removed 
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with a Whatman filterpaper (GE Healthcare, Piscataway, NJ) 
and the samples were stained with 0.75% uranyl formate for 
30 seconds. After removing the excess uranyl formate with 
a filter paper the grids were examined in a JEOL 1200EX 
Transmission EM or a TecnaiG2 Spirit BioTWIN and images 
were recorded with an AMT 2k CCD camera.
Cryo-transmission EM. CSF and plasma samples were 
preserved in vitrified ice supported by holey carbon films 
on 400-mesh copper grids. Each sample was prepared by 
applying a 3 μl drop of sample suspension to a cleaned grid, 
blotting away with filter paper, and immediately proceeding 
with vitrification in liquid ethane. Grids were stored under liq-
uid nitrogen until transferred to the EM for imaging. EM was 
performed using an FEI Tecnai T12 EM, operating at 120keV 
equipped with an FEI Eagle 4k x4k CCD camera. Vitreous 
ice grids were transferred into the EM using a cryostage that 
maintains the grids at a temperature below −170 °C. Images 
on each grid were acquired at multiple scales to assess the 
overall distribution of the specimen. After identifying poten-
tially suitable target of areas for imaging at lower magnifica-
tions, pairs of high magnification images were acquired at 
normal magnifications of 110,000×, 52,000×, and 21,000×.
Quantitative RT-PCR. mRNA was reverse transcribed into 
cDNA using the SuperScript VILO cDNA synthesis kit (Invi-
trogen, Carlsbad, CA). To determine the copy number of 
IDH1 transcripts, we performed quantitative PCR on the 
cDNA. Reactions were done in a 25 μl reaction using Power 
SYBR Green PCR Master Mix (Applied Biosystems, Foster 
City, CA) and 160 nmol/l of each primer. Amplification condi-
tions consisted of: (i) 1 cycle of 50 °C, 2 minutes; (ii) 1 cycle 
of 95 °C, 10 minutes; (iii) 40 cycles of 95 °C, 15 seconds; 
and 60 °C, 1 minute, and (iv) a dissociation stage consist-
ing of 1 cycle of 95 °C, 15 seconds; 60 °C, 20 seconds; 
and 95 °C, 15 seconds on the 7000 ABI Prism PCR sys-
tem (Applied Biosystems). Ct values were analyzed in auto 
mode and manually inspected for accuracy. Primer dimers 
were excluded by evaluation of dissociation curve and aga-
rose gel electrophoresis. The following IDH1 primers were 
used: Forward: CGGTCTTCAGAGAAGCCATT and Reverse: 
AGGCCCAGGAACAACAAAAT.
Pre-amplification of IDH1 cDNA. We performed IDH1 PCR 
on the cDNA derived from EV RNA using forward (5′-TCCC 
GCGAAATTAATACGACCGGTCTTCAGAGAAGCCATT-3′) 
and reverse (5′-GCTGGAGCTCTGCAGCTAAGGCCCAG 
GAACAACAAAAT-3′) primers flanking nucleotide position 
395 of the IDH1 transcript, where lower case letters denote 
universal primer sequences and upper case letters denote 
IDH1 specific primer sequences. Ten μl of cDNA was split into 
two PCR reactions, each performed in 50 μl volumes contain-
ing 5 μl cDNA, 1 U of Phusion Hot Start II DNA Polymerase 
(New England Biolabs, Ipswich, MA), 1X Phusion HF buffer 
(New England Biolabs), 0.2 mmol/l dNTP mix (Invitrogen), 
and 0.2 μmol/l of each primer. Amplification was done in a 
Veriti Thermal Cycler (Applied Biosystems) using the follow-
ing conditions: 98 °C for 3 minutes; 10 cycles of 98 °C for 
10 seconds, 68 °C for 15 seconds (−0.5 °C/cycle), 72 °C for 
10 seconds; 30 cycles of 98 °C for 10 seconds, 62 °C for 15 
seconds, 72 °C for 10 seconds; 1 cycle of 72 °C for 5 minutes. 
The PCR products for each sample were then pooled and 
purified using a QIAquick PCR purification column (Qiagen) 
and the concentration determined using a 2100 Bioanalyzer 
with a DNA 1000 LabChip kit (Agilent).
EV-BEAMing PCR. PCR amplicons from each sample were 
used as templates for each BEAMing analysis. We per-
formed the BEAMing PCR using a protocol slightly modi-
fied from that previously described.11
 We set up 150 μl PCR 
reactions containing 10 μl 20 pmol/l template DNA, 2X TITA-
NIUM Taq DNA Polymerase (Clontech, Mountain View, CA), 
1X TITANIUM Taq buffer (Clontech), 1 mmol/l dNTP mix, 
8.3 mmol/l MgCl2 (Invitrogen), 0.05 μmol/l universal forward 
primer (5′-tcccgcgaaattaatacgac-3′), 8 μmol/l nested reverse 
primer (5′-AATCAGTTGCTCTGTATTGATCC-3′), and 6 × 107 
magnetic streptavidin beads (MyOne, Invitrogen) coated 
with a modified universal forward primer (5′-dual biotion-T-
Spacer18-tcccgcgaaattaatacgac-3′). The aqueous reaction 
mixture was then combined with 600 μl of an oil/emulsifier 
mixture of 7% w/v ABIL WE09 (Degussa, Essen, GE), 20% 
v/v M3516 mineral oil (Sigma-Aldrich, St Louis, MO) and 73% 
v/v Tegosoft DEC (Degussa), and one 5 mm steel bead (Qia-
gen) in one well of a 96-deep-well plate (Abgene, Lafayette, 
CO). The plate was shaken in a TissueLyser (Qiagen) for 10 
seconds at 15 Hz and then 7 seconds at 17 Hz, and 80 μl of 
the emulsions were distributed into each well of a MicroAmp 
96-well PCR plate (PE Biosystems, Carslbad, CA). The emul-
sion PCR was done in a Veriti Thermal Cycler set to a 20% 
temperature ramp rate to prevent disruption of the emulsions, 
with the following cycling conditions: 94 °C for 3 minutes; 12 
cycles of 94 °C for 10 seconds, 65 °C for 45 seconds (−0.5 °C/
cycle), 70 °C for 75 seconds; 50 cycles of 94 °C for 10 sec-
onds, 59 °C for 45 seconds, 70 °C for 75 seconds; 1 cycle of 
70 °C for 5 minutes. We broke the emulsions by adding 150 μl 
breaking buffer (10 mmol/l Tris–HCl, pH 7.5, 1% Triton X-100, 
1% SDS, 100 mmol/l NaCl, 1 mmol/l EDTA) to each well and 
mixing the samples with a TissueLyser (Qiagen) at 20 Hz for 
30 seconds. The samples were then centrifuged at 3,200g 
for 2 minutes and the oil phase was removed. We performed 
this breaking procedure twice and then combined and resus-
pended all of the beads for each respective sample in 100 μl 
wash buffer (20 mmol/l Tris–HCl, pH 8.4, 50 mmol/l KCl). The 
beads were incubated with 0.1 mol/l NaOH to remove non-
biotinylated DNA, and then washed and resuspended in 100 
μl wash buffer.
Mutational analysis. We interrogated the mutational sta-
tus of the bead-bound DNA using three fluorescent 
oligonucleotides: an Alexa Fluor 488 (AF488)–labeled oli-
gonucleotide (5′-AF488-ATAAGCATGACGACCTATGAT-3′) 
specific to the wild-type IDH1 sequence, an Alexa Fluor 647 
(AF647)–labeled oligonucleotide (5′-AF647-ATAAGCATGAT 
GACCTATGAT-3′) specific to the A395 IDH1 variant, and a 
PB-labeled control oligonucleotide (5′-PB-TTTTACCCATC 
CACTCACAA-3′) specific to a sequence region shared by 
both wild-type and mutant IDH1 variants. The oligohybridiza-
tion was in a 100 μl hybridization mixture of 30 μl beads, 66 
μl hybridization buffer (3 mol/l tetramethylammonium chloride 
(Sigma-Aldrich), 50 mmol/l Tris–HCl, pH 7.5, 4 mmol/l EDTA) 
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and 4 μl of a mixture of the oligonucleotides, each at 5 μmol/l. 
Samples were heated to 70 °C for 10 seconds, cooled to 
35 °C at 0.1 °C/second, incubated at 35 °C for 2 minutes, 
and finally cooled to 25 °C at 0.1 °C/second using a Veriti 
Thermal Cycler. The beads were collected, washed in 100 μl 
hybridization buffer at 48 °C for 5 minutes, and then 100 μl 
wash buffer at room temperature, before a final resuspension 
in 400 μl wash buffer. We analyzed all oligohybridized beads 
using an LSR II flow cytometer (BD Biosciences) and pro-
cessed the data using FACSDiva software (BD Biosciences). 
Events were gated to exclude doublets, aggregates, and 
beads without IDH1 amplicons. At least 100,000 events were 
counted and the mutant signal was calculated using events 
that had either wild-type or mutant fluorescence, but not both.
Digital droplet PCR methods.
Reaction preparation: Pre-amplified PCR product was 
diluted and added to the reaction mixture. Primers and fluo-
rescent Taqman MGB probes (FAM-labeled G395A-5′- ATA 
AGCATGATGACCTATGAT-3′ and VIC-labeled WT- ATAAG 
CATGACGACCTATGAT-3′) were designed using Applied 
 Biosystems’ Custom TaqMan Assay Design Tool. The final 
IDH1 assay mix contained 900 μmol/l forward and reverse 
primers, 200 nmol/l VIC-labeled WT IDH1 probe, and 200 
nmol/l FAM-labeled G395A probe. The PCR reaction was 
prepared in 25 μl final volume, using 12.5 μl TaqMan Geno-
typing Master Mix (Life Technologies), 2.5 μl Droplet Stabi-
lizer (RainDance Technologies, Lexington, MA), 2.5 μl Assay 
Mix (10×) and 7.5 μl cDNA template in water.
Digital droplet assay: Droplets containing PCR reaction com-
ponents were generated using a hydrodynamic flow-focus-
ing microfluidic chip (RainDrop Source chip; RainDance 
Technologies), deposited into PCR tubes as 5 pl aqueous 
droplets suspended in inert fluorinated oil (REB Carrier Oil; 
RainDance Technologies), and subjected to PCR amplifica-
tion in a thermal cycler (Mastercycler pros; Eppendorf, Ham-
burg, Germany). PCR cycling parameters: 10 minutes 95 °C, 
then 44 cycles of 95 °C for 15 seconds and 60 °C for 1 min-
ute. After PCR completion, the emulsion was injected into a 
second microfluidic chip (RainDrop Sense chip; RainDance 
Technologies) for fluorescence measurement. Following 
488 nm excitation, droplet fluorescence was detected through 
filters (FAM and VIC centered emission) with photomultiplier 
tubes recording fluorescence intensity (“height”) and duration 
(“width”). Spectral crosstalk-corrected data from each sample 
or control were converted to a two-dimensional (FAM and 
VIC intensity) histogram (electronic and photonic noise was 
removed, droplet data were width filtered and normalized to 
background fluorescence). Custom software (RainDrop Ana-
lyst; RainDance Technologies) was used to define graphical 
areas or “gates” associated with each allele type and count 
the number of droplets within each gate.
Supplementary material
Figure S1. RNA profiles from CSF and serum EVs.
Acknowledgments. This work was supported by NIH/NCI 
grants CA069246 (F.H., X.O.B., B.C.); CA141226 (X.O.B.); 
CA156009 (X.O.B.); and CA141150 (X.O.B.); Brain Tumor 
Funders’ Collaborative (B.C., X.O.B.); American Brain Tumor 
Association (ABTA; J.S.); Harvard Catalyst (B.C.); A Reason To 
Ride research fund (E.T.W.); Hyugens Scholarship NL (L.B.), 
the Richard Floor Biorepository and the Accelerate Brain Can-
cer Cure (ABC2). All processing of samples by Exosome Di-
agnostics Inc and RainDance Technologies was carried out on 
de-identified samples. We thank Suzanne McDavitt for skilled 
editorial assistance. We thank N Agrawal for his advice and 
for providing us with BEAMing reagents and A Mandinova for 
providing access to the TissueLyser. We thank Karen Messer 
for help with statistical analysis. We also thank Winston Patrick 
Kuo and Fatemeh Momen-Heravi for help with TEM and Mik-
kel Noerholm for help with probe design. J.S. is an inventor on 
the microvesicle technology used in this study which has been 
licensed to Exosome Diagnostics, Inc. He holds equity in, and 
is an employee of that company. Breakefield and Carter are on 
the Scientific Advisory Board of the company for which they 
receive cash compensation. M.L.S. and S.K.K. are employees 
of RainDance Technologies Inc. The other authors declared 
no conflict of interest.
1. Lecomte, T, Ceze, N, Dorval, E and Laurent-Puig, P (2010). Circulating free tumor DNA 
and colorectal cancer. Gastroenterol Clin Biol 34: 662–681.
2. Schwarzenbach, H, Hoon, DS and Pantel, K (2011). Cell-free nucleic acids as biomarkers 
in cancer patients. Nat Rev Cancer 11: 426–437.
3. Balaj, L, Lessard, R, Dai, L, Cho, YJ, Pomeroy, SL, Breakefield, XO et al. (2011). Tumour 
microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat 
Commun 2: 180.
4. Skog, J, Würdinger, T, van Rijn, S, Meijer, DH, Gainche, L, Sena-Esteves, M et al. (2008). 
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and 
provide diagnostic biomarkers. Nat Cell Biol 10: 1470–1476.
5. Noerholm, M, Balaj, L, Limperg, T, Salehi, A, Zhu, LD, Hochberg, FH et al. (2012). RNA 
expression patterns in serum microvesicles from patients with glioblastoma multiforme and 
controls. BMC Cancer 12: 22.
6. Hong, BS, Cho, JH, Kim, H, Choi, EJ, Rho, S, Kim, J et al. (2009). Colorectal cancer cell-
derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation 
of endothelial cells. BMC Genomics 10: 556.
7. Di Vizio, D, Kim, J, Hager, MH, Morello, M, Yang, W, Lafargue, CJ et al. (2009). Oncosome 
formation in prostate cancer: association with a region of frequent chromosomal deletion in 
metastatic disease. Cancer Res 69: 5601–5609.
8. Street, JM, Barran, PE, Mackay, CL, Weidt, S, Balmforth, C, Walsh, TS et al. (2012). 
Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl 
Med 10: 5.
9. Weston, CL, Glantz, MJ and Connor, JR (2011). Detection of cancer cells in the 
cerebrospinal fluid: current methods and future directions. Fluids Barriers CNS 8: 14.
10. Thelwell, N, Millington, S, Solinas, A, Booth, J and Brown, T (2000). Mode of action and 
application of Scorpion primers to mutation detection. Nucleic Acids Res 28: 3752–3761.
11. Diehl, F, Li, M, He, Y, Kinzler, KW, Vogelstein, B and Dressman, D (2006). BEAMing: single-
molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 3: 551–559.
12. He, Y, Wu, J, Dressman, DC, Iacobuzio-Donahue, C, Markowitz, SD, Velculescu, VE et al. 
(2010). Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature 
464: 610–614.
13. Li, M, Chen, WD, Papadopoulos, N, Goodman, SN, Bjerregaard, NC, Laurberg, S et 
al. (2009). Sensitive digital quantification of DNA methylation in clinical samples. Nat 
Biotechnol 27: 858–863.
14. Diehl, F, Schmidt, K, Durkee, KH, Moore, KJ, Goodman, SN, Shuber, AP et al. (2008). 
Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. 
Gastroenterology 135: 489–498.
15. Taly, V, Pekin, D, El Abed, A and Laurent-Puig, P (2012). Detecting biomarkers with 
microdroplet technology. Trends Mol Med 18: 405–416.
16. Pekin, D, Skhiri, Y, Baret, JC, Le Corre, D, Mazutis, L, Salem, CB et al. (2011). 
Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. 
Lab Chip 11: 2156–2166.
17. Zhong, Q, Bhattacharya, S, Kotsopoulos, S, Olson, J, Taly, V, Griffiths, AD et al. (2011). 
Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR. Lab 
Chip 11: 2167–2174.
18. Didelot, A, Kotsopoulos, SK, Lupo, A, Pekin, D, Li, X, Atochin, I et al. (2013). Multiplex 
picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical 
samples. Clin Chem 59: 815–823.
Molecular Therapy—Nucleic Acids
CSF-derived EVs as Platform for Biomarker Detection
Chen et al.
10
19. Dang, L, White, DW, Gross, S, Bennett, BD, Bittinger, MA, Driggers, EM et al. (2009). 
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739–744.
20. Figueroa, ME, Abdel-Wahab, O, Lu, C, Ward, PS, Patel, J, Shih, A et al. (2010). Leukemic 
IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, 
and impair hematopoietic differentiation. Cancer Cell 18: 553–567.
21. Sjöblom, T, Jones, S, Wood, LD, Parsons, DW, Lin, J, Barber, TD et al. (2006). The 
consensus coding sequences of human breast and colorectal cancers. Science 314: 
268–274.
22. Parsons, DW, Jones, S, Zhang, X, Lin, JC, Leary, RJ, Angenendt, P et al. (2008). An 
integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807–1812.
23. Cancer Genome Atlas Research Network (2008). Comprehensive genomic 
characterization defines human glioblastoma genes and core pathways. Nature 455: 
1061–1068.
24. Yan, H, Parsons, DW, Jin, G, McLendon, R, Rasheed, BA, Yuan, W et al. (2009). IDH1 
and IDH2 mutations in gliomas. N Engl J Med 360: 765–773.
25. Verhaak, RG, Hoadley, KA, Purdom, E, Wang, V, Qi, Y, Wilkerson, MD et al.; Cancer 
Genome Atlas Research Network. (2010). Integrated genomic analysis identifies clinically 
relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, 
EGFR, and NF1. Cancer Cell 17: 98–110.
26. Labussière, M, Idbaih, A, Wang, XW, Marie, Y, Boisselier, B, Falet, C et al. (2010). All the 
1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74: 1886–1890.
27. SongTao, Q, Lei, Y, Si, G, YanQing, D, HuiXia, H, XueLin, Z et al. (2012). IDH mutations 
predict longer survival and response to temozolomide in secondary glioblastoma. Cancer 
Sci 103: 269–273.
28. Yen, KE, Bittinger, MA, Su, SM and Fantin, VR (2010). Cancer-associated IDH mutations: 
biomarker and therapeutic opportunities. Oncogene 29: 6409–6417.
29. Capper, D, Simon, M, Langhans, CD, Okun, JG, Tonn, JC, Weller, M et al.; German 
Glioma Network. (2012). 2-Hydroxyglutarate concentration in serum from patients with 
gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer 131: 
766–768.
30. Taniguchi, K, Uchida, J, Nishino, K, Kumagai, T, Okuyama, T, Okami, J et al. (2011). 
Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung 
adenocarcinomas. Clin Cancer Res 17: 7808–7815.
31. Higgins, MJ, Jelovac, D, Barnathan, E, Blair, B, Slater, S, Powers, P et al. (2012). 
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin 
Cancer Res 18: 3462–3469.
32. Chen, C, Skog, J, Hsu, CH, Lessard, RT, Balaj, L, Wurdinger, T et al. (2010). Microfluidic 
isolation and transcriptome analysis of serum microvesicles. Lab Chip 10: 505–511.
33. Shao, H, Chung, J, Balaj, L, Charest, A, Bigner, DD, Carter, BS et al. (2012). Protein 
typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat 
Med 18: 1835–1840.
34. Shi, WM, Wildrick, DM and Sawaya, R (1998). Volumetric measurement of brain tumors 
from MR imaging. J Neurooncol 37: 87–93.
Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)
Molecular Therapy–Nucleic Acids is an open-access jour-
nal published by Nature Publishing Group. This work is 
licensed under a Creative Commons Attribution-NonCommercial-
Share Alike 3.0 Unported License. To view a copy of this license, visit 
http://creativecommons.org/licenses/by-nc-sa/3.0/
